# Michigan’s $3B Cannabis Industry Faces Pressure Amid Tax Repeal Push > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-tax-repeal-impact-michigan-industry-pressure/ > **Published:** 2026-04-24T20:49:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:36:11-04:00 > **Clinical Summary:** Explore the cannabis tax repeal impact on Michigan’s $3B industry and how lawmakers’ decisions affect patient access and market dynamics. --- ✦ New CED Clinical Relevance #18 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryTHC Clinical Summary Michigan’s cannabis industry is facing significant economic pressure as state lawmakers consider repealing a recently implemented 24% excise tax that has generated approximately $3 billion in revenue. The tax increase has reportedly reduced consumer demand and disadvantaged legal retailers competing against illicit market alternatives, which offer lower prices without tax burden. For clinicians and patients, this regulatory uncertainty directly impacts access and affordability of legal cannabis products, particularly for those using cannabis therapeutically for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), nausea, or epilepsy-related seizures. Tax-driven price increases may push patients toward unregulated black market products with unknown potency, contaminants, and quality standards, undermining clinical safety and the ability to monitor standardized dosing. Additionally, reduced tax revenue threatens funding for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), education, and public health initiatives that support evidence-based clinical practice. Clinicians should remain aware of their patients’ cost barriers to accessing regulated products and consider how local tax policy influences medication adherence and the risk of exposure to untested cannabis formulations. Dr. Caplan’s Take “Michigan’s proposed 24% tax increase fundamentally misunderstands how cannabis patients respond to pricing, and I’ve seen this play out clinically for two decades: when legal products become unaffordable, patients don’t stop using cannabis, they return to illicit sources where we lose all quality control and dosing reliability. The state should recognize that a sustainable cannabis tax policy requires keeping legal products competitive enough that patients with legitimate therapeutic needs can actually access them.” Clinical Perspective Michigan’s proposed 24% tax increase on cannabis—intended to fund public health and regulatory infrastructure—faces industry pushback that could reshape market dynamics and ultimately affect patient access and product safety in clinical settings. While higher taxes theoretically reduce consumption and increase revenue for harm-reduction programs, they may also drive patients toward illicit markets where quality control is absent, potentially exposing users to contaminated or mislabeled products with unpredictable cannabinoid profiles. Clinicians should recognize that tax policy operates as an upstream social determinant of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns; lower retail prices from tax repeals may increase patient use and associated healthcare burdens, while aggressive taxation could paradoxically worsen outcomes for those who self-medicate for [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) or mental health conditions by reducing legitimate access. The complexity here involves balancing public health revenue needs against unintended consequences of pricing mechanisms on vulnerable populations. Practical guidance for providers should include explicit screening conversations about cannabis sour 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Michigan%E2%80%99s%20%243B%20%3Cb%3ECannabis%3C%2Fb%3E%20Industry%20is%20Under%20Pressure%20as%20Lawmakers%20Push%20to%20Repeal%20New%2024%25%20Tax%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fmichigans-3b-cannabis-industry-is-under-pressure-as-lawmakers-push-to-repeal-new-24-tax%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fmichigans-3b-cannabis-industry-is-under-pressure-as-lawmakers-push-to-repeal-new-24-tax%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Michigan%E2%80%99s%20%243B%20%3Cb%3ECannabis%3C%2Fb%3E%20Industry%20is%20Under%20Pressure%20as%20Lawmakers%20Push%20to%20Repeal%20New%2024%25%20Tax%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fmichigans-3b-cannabis-industry-is-under-pressure-as-lawmakers-push-to-repeal-new-24-tax%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New state law could hamstring Ohio’s struggling hemp industry – Farm and Dairy](https://cedclinic.com/new-state-law-could-hamstring-ohios-struggling-hemp-industry-farm-and-dairy/) Learn about new legislation impacting Ohio’s hemp industry and its potential effects on growers and businesses. [Read More](https://cedclinic.com/new-state-law-could-hamstring-ohios-struggling-hemp-industry-farm-and-dairy/) [Study Finds Licensed Cannabis Farms More Effective Than Bans in Deterring Unlicensed Cultivation](https://cedclinic.com/study-finds-licensed-cannabis-farms-more-effective-than-bans-in-deterring-unlicensed-cultivation/) Explore research showing how licensed cannabis farms help reduce unlicensed cultivation and support regulated markets. [Explore Study](https://cedclinic.com/study-finds-licensed-cannabis-farms-more-effective-than-bans-in-deterring-unlicensed-cultivation/) [California Bill to Authorize Medical Cannabis Drive-Thrus Advances to Assembly Floor Vote](https://cedclinic.com/california-bill-to-authorize-medical-cannabis-drive-thrus-advances-to-assembly-floor-vote/) Stay updated on California’s legislative efforts to improve [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) through drive-thru services. [Learn More](https://cedclinic.com/california-bill-to-authorize-medical-cannabis-drive-thrus-advances-to-assembly-floor-vote/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).